Article Sidebar
Views PDF: 281
CONSTRUCT THE MODEL OF BUDGET IMPACT ANALYSIS OF RUXOLITINIB IN PRIMARY MYELOFIBROSIS IN VIETNAM
Main Article Content
Abstract
Primary myelofibrosis (PMF) is the hematologic disease which has the most unfavorable prognosis in the group of myeloproliferative neoplasms diseases. Ruxolitinib (RUX) has been shown to significantly reduce spleen volume and risk of death compared with the best available therapy (BAT) in PMF treatment. With high drug costs, it is necessary to consider the feasibility of drug selection in clinical practice based on budget impact analysis (BIA), in which constructing model is considered one of the most important steps, deciding the feasibility and reliability of BIA. With modeling research method combined with literature review and indepth-interview with clinical experts, the BIA model has been built based on MS Microsoft Excel 2013 software with model structure including calculation pages for outcome parameters (budget impact and effectiveness impact) for 2 scenarios without RUX and with RUX. The model allows to conduct BIA of RUX with different health insurance payments in PMF as well as evaluate the effectiveness impact of treatment between the two research scenarios.
Article Details
Keywords
Budget impact analysis, ruxolitinib, primary myelofibrosis, model
References
2. Harrison CN, Vannucchi AM, Kiladjian J-J, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701-1707.
3. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047-4053.
4. Hickey N, Corcoran A, Usher C, Barry M, McCullagh L. 2017; A462. Available at. Accessed 9, 20.
5. Marshall DA, Douglas PR, Drummond MF, et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Pharmacoeconomics. 2008;26(6):477-495.
6. Gómez-Casares MT, Hernández-Boluda JC, Jiménez-Velasco A, et al. Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain. Journal of Health Economics and Outcomes Research. 2017;5(2):162-174.